Wolfe Research analyst Tim Anderson upgraded Sanofi to Outperform from Peer Perform with a EUR 105 price target. The analyst sees a better entry point following the recent pullback and views Sanofi as a “steady grower,” mainly supported by Dupixent. The firm also sees significantly fewer patent expiries versus peers for the company until the early 2030s.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNY:
- AstraZeneca (NASDAQ:AZN) Gains on New Drug
- Exscientia expands Sanofi deal, eligible for $45M in milestones plus incentives
- Sanofi discontinuing tusamitamab ravtansine after trial did not meet endpoint
- Sanofi exercises option to license NK cell engager program from Innate Pharma
- Sanofi says EMA gives positive opinion of Fexinidazole Winthrop for rhodesiense